Y
Yuki Kojima
Publications - 3
Citations - 50
Yuki Kojima is an academic researcher. The author has contributed to research in topics: Cancer & Biopsy. The author has an hindex of 2, co-authored 3 publications receiving 14 citations.
Papers
More filters
Journal ArticleDOI
Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
Shu Yazaki,Tatsuya Yoshida,Yuki Kojima,Shigehiro Yagishita,Hiroko Nakahama,Keiji Okinaka,Hiromichi Matsushita,Mika Shiotsuka,Osamu Kobayashi,Satoshi Iwata,Yoshitaka Narita,Akihiro Ohba,Masamichi Takahashi,Satoru Iwasa,Kenya Kobayashi,Yuichiro Ohe,Tomokazu Yoshida,Akinobu Hamada,Toshihiko Doi,Noboru Yamamoto +19 more
TL;DR: In this paper, the authors evaluated serum SARS-CoV-2 antibody status in patients with cancer and health care workers (HCWs) during the COVID-19 pandemic in Japan.
Journal ArticleDOI
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix.
Takaaki Mizuno,Yuki Kojima,Kan Yonemori,Hiroshi Yoshida,Yukiko Sugiura,Yohei Ohtake,Hitomi Sumiyoshi Okuma,Tadaaki Nishikawa,Maki Tanioka,Kazuki Sudo,Akihiko Shimomura,Emi Noguchi,Tomoyasu Kato,Tatsunori Shimoi,Masaya Uno,Mitsuya Ishikawa,Yasuhiro Fujiwara,Yuichiro Ohe,Kenji Tamura +18 more
TL;DR: The results suggested that HER3 overexpression may be an independent risk factor for post-operative recurrence in patients with early-stage AC and ASC of the cervix and the prognostic value of HER3 should be confirmed in a larger sample.
Journal ArticleDOI
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
Takaaki Mizuno,Yuki Kojima,Kan Yonemori,Hiroshi Yoshida,Yukiko Sugiura,Yohei Ohtake,Hitomi Sumiyoshi Okuma,Tadaaki Nishikawa,Maki Tanioka,Kazuki Sudo,Akihiko Shimomura,Emi Noguchi,Tomoyasu Kato,Tatsunori Shimoi,Masaya Uno,Mitsuya Ishikawa,Yasuhiro Fujiwara,Yuichiro Ohe,Kenji Tamura +18 more
TL;DR: Her3 overexpression was revealed to be common among patients with ovarian cancer, especially in those with non-HGSC histology and neoadjuvant chemotherapy, and may be promoted by chemotherapy.